Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DPP-IV Inhibitor
DPP- Inhibitor · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DPP-IV Inhibitor | DRUG | Escalating doses po bid or qd |
| Placebo | DRUG | po bid or qd |
| Metformin | DRUG | As prescribed |
Inclusion Criteria: * adult patients 18-75 years of age; * type 2 diabetes diagnosed \>=1 month before screening; * no previous treatment, or previous treatment with no more than 2 oral medications. Exclusion Criteria: * type 1 diabetes; * type 2 diabetes treated with insulin or a PPAR gamma agon...
DPP- Inhibitor is being studied for the treatment of Diabetes Mellitus Type 2, a metabolic condition. It is an investigational small molecule developed by Roche Holding AG. The clinical program has focused on adults with type 2 diabetes, with two completed Phase 2 trials enrolling a combined 509 participants.
DPP- Inhibitor is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored the Phase 2 clinical program evaluating the compound in patients with Diabetes Mellitus Type 2. The program includes two completed trials conducted across sites in the United States, Europe, Latin America, and Australia.
DPP- Inhibitor is in Phase 2 clinical development. Both of its Phase 2 trials in Diabetes Mellitus Type 2 have been completed, and no trials are currently listed as active. The studies together enrolled 509 participants. It is an investigational agent and has not been approved for any indication.
Two completed Phase 2 trials have evaluated DPP- Inhibitor in Diabetes Mellitus Type 2. NCT00111670 enrolled 291 patients across the United States, Bulgaria, Costa Rica, Estonia, Latvia, Lithuania, Mexico, Puerto Rico, and Romania. NCT00111631 enrolled 218 patients across the United States, Australia, Canada, Germany, Italy, and Puerto Rico. Both were randomized, double-blind, and placebo-controlled.
Yes, DPP- Inhibitor and DPP-IV Inhibitor refer to the same agent. DPP-IV Inhibitor is an alternative name used for this Roche Holding AG compound in its Phase 2 program for Diabetes Mellitus Type 2. Searches using either name point to the same investigational small molecule and the same two completed clinical trials.
Both DPP- Inhibitor Phase 2 trials in Diabetes Mellitus Type 2 were randomized, double-blind, and placebo-controlled. NCT00111670 enrolled 291 participants and NCT00111631 enrolled 218, for a total of 509. Eligible patients were 18 years or older, and both sexes were included. Neither trial selected patients by biomarker.